The Global Health Body Sounds Concern Over Acute Lack of Weight-Loss Medications
Fewer than one in 10 people eligible to benefit from obesity jabs like Wegovy have access to them, warns the WHO as it releases its first advice on the medications.
Given more than one billion individuals worldwide now obese, it is advocating for increased and just access to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that obesity is a chronic disease that can be addressed with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major hurdles to universal availability to the treatments that can assist patients in reducing substantial weight, explains the agency.
Weight-Loss Drug Shortage
Despite the present most favorable scenario, the manufacturing of these medications might only reach around 100 million people – less than 10% of the global need, according to the health organization.
The recommendation encourages nations and manufacturers to increase access, by approaches including voluntary licensing.
The intellectual property rights on a key compound – the main ingredient of a leading brand – is due to expire in multiple countries in 2026.
How Obesity Jabs Operate
These medications mimick a biological compound to slow digestion, suppress the appetite and increase feelings of fullness so users consume fewer calories.
People usually begin shedding pounds after several weeks of starting on the regular doses.
Evidence indicates patients may see weight return after a year of halting the medication, as their usual food cravings return.
Being carrying excess weight elevates your risk for developing medical conditions, including diabetes, heart disease, brain attack, and certain malignancies.
Obesity affects individuals in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
